University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

The Testosterone Trials in Older Men

Phase 3

Completed

Conditions: Andropause

Interventions: Drug: Placebo
Drug: AndroGel® (testosterone gel)

First Posted Date: 2008-12-01

Last Posted Date: 2019-02-21

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 790

Registration Number: NCT00799617

Locations: 🇺🇸
Center for Men's Health LA BioMed at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 9 locations

Patient Feedback Effectiveness Study

Not Applicable

Completed

Conditions: Substance Use Disorders

Interventions: Behavioral: Patient Feedback

First Posted Date: 2008-11-25

Last Posted Date: 2012-01-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 118

Registration Number: NCT00798044

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Drug: Growth hormone releasing hormone/ placebo

First Posted Date: 2008-11-17

Last Posted Date: 2019-07-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 3

Registration Number: NCT00791843

Locations: 🇺🇸
Massachusetts General Hospital/ Geriatric Research, Boston, Massachusetts, United States

Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site

Phase 2

Completed

Conditions: Opiate Addiction

Interventions: Other: Treatment as Usual (TAU)
Drug: Depot naltrexone

First Posted Date: 2008-10-29

Last Posted Date: 2017-10-23

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 308

Registration Number: NCT00781898

Locations: 🇺🇸
Treatment Research Center, Philadelphia, Pennsylvania, United States

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: CG100649 (2 mg)
Drug: CG100649 (8 mg)
Drug: Celecoxib
Drug: Acetazolamide
Drug: Placebo capsules
Drug: Naproxen

First Posted Date: 2008-10-27

Last Posted Date: 2014-02-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 26

Registration Number: NCT00780325

Locations: 🇺🇸
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

Phase 2

Completed

Conditions: Cocaine Dependence
Alcohol Dependence

Interventions: Drug: VIVITROL (Naltrexone extended-release injectable suspension)
Drug: Placebo

First Posted Date: 2008-10-22

Last Posted Date: 2018-01-26

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 80

Registration Number: NCT00777062

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Not Applicable

Completed

Conditions: Pre-diabetes
Type 2 Diabetes

Interventions: Drug: Exenatide
Drug: Sitagliptin
Drug: Glimepiride

First Posted Date: 2008-10-20

Last Posted Date: 2022-06-07

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 47

Registration Number: NCT00775684

Locations: 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Clinical and Translational Research Center, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

Phase 1

Completed

Conditions: HIV Infection

Interventions: Biological: PLACEBO
Biological: PENNVAX-B
Biological: GENEVAX IL-12-4532
Biological: IL-15 adjuvant

First Posted Date: 2008-10-20

Last Posted Date: 2016-08-25

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 38

Registration Number: NCT00775424

Locations: 🇺🇸
University of Pennsylvania. Clinical Trials Unit, Philadelphia, Pennsylvania, United States

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Phase 2

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Recombinant human Growth Hormone

First Posted Date: 2008-10-03

Last Posted Date: 2019-11-18

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 63

Registration Number: NCT00766038

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Center for NeuroSkills, Bakersfield, California, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States

Depot Naltrexone Treatment of Opioid Dependent Parolees

Not Applicable

Completed

Conditions: Opioid Dependence

Interventions: Drug: Depot Naltrexone

First Posted Date: 2008-09-22

Last Posted Date: 2019-04-23

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 61

Registration Number: NCT00756990

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy